- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | H.C. Wainwright maintains BiomX stock Buy rating, $21 target | 5 | Investing.com | ||
| Di | BiomX stock target soars to $21 on Phase 2 trial success | 2 | Investing.com | ||
| Di | BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure | 72 | GlobeNewswire (Europe) | NESS ZIONA, Israel, April 01, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies... ► Artikel lesen | |
| Mo | BiomX's bacteria-killing virus reduces diabetic bone ulcers in midstage test | 2 | FierceBiotech | ||
| BIOMX Aktie jetzt für 0€ handeln | |||||
| Mo | BiomX Reports Positive BX211 Trial Results In Diabetic Foot Osteomyelitis; Plans Phase 2/3 Trial | 1 | RTTNews | ||
| Mo | BiomX reports progress in diabetic ulcer treatment | - | Investing.com | ||
| Mo | BiomX meldet Fortschritte bei der Behandlung von diabetischen Geschwüren | 2 | Investing.com Deutsch | ||
| Mo | BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO) | 63 | GlobeNewswire (Europe) | BX211 was safe and well-toleratedBX211 produced sustained and statistically significant1 Percent Area Reduction (PAR) of ulcer size (p = 0.046 at week 12; p=0.052 at week 13), with a separation from... ► Artikel lesen | |
| 26.03. | BiomX reduziert Verluste und zeigt Fortschritte im Jahresvergleich | 2 | IT BOLTWISE | ||
| 25.03. | BiomX Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 25.03. | BiomX Inc. Full Year Profit Falls | - | RTTNews | ||
| 25.03. | BiomX Inc. - 8-K, Current Report | - | SEC Filings | ||
| 25.03. | BiomX GAAP EPS of -$3.36 misses by $2.14 | 1 | Seeking Alpha | ||
| 25.03. | BiomX Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business and Program Updates | 86 | GlobeNewswire (Europe) | In February 2025, BiomX announced a series of financings with total gross proceeds of approximately $12 million to support completion of Phase 2b study of BX004; topline results anticipated in Q1... ► Artikel lesen | |
| 19.03. | BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025 | 2 | GlobeNewswire (USA) | ||
| 27.02. | BiomX Inc. - 8-K, Current Report | - | SEC Filings | ||
| 26.02. | BiomX announces series of financings for aggregate gross proceeds of $12M | 2 | Seeking Alpha | ||
| 16.12.24 | BiomX regains compliance with NYSE American's listing rule | 2 | Seeking Alpha | ||
| 16.12.24 | BiomX Inc. - 8-K, Current Report | - | SEC Filings | ||
| 16.12.24 | BiomX Inc. Receives Notice of Compliance with NYSE American Continued Listing Standards | 112 | GlobeNewswire (Europe) | NESS ZIONA, Israel, Dec. 16, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that... ► Artikel lesen |
Seite:
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 80,50 | -3,77 % | BioNTech-Aktie: Sie haben keine Ahnung! | News von Trading-Treff.de Für BioNTech ist aktuell der Trend nach unten gerichtet. Auch am Freitag ging es um über 1,2 % abwärts. Die Aktie war in den vergangenen Wochen schon der Katastrophe nahe.... ► Artikel lesen | |
| AMGEN | 268,60 | -0,17 % | Amgen: Uplizna (inebilizumab-cdon) Is Now The First And Only FDA-approved Treatment For Igg4-related Disease | Breakthrough CD19+ B-Cell Targeted Therapy Delivered an 87% Reduction in the Risk of Flares Versus Placebo
UPLIZNA Shown to Deliver Corticosteroid-Free, Flare-Free... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,400 | -2,10 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights | Significant progress toward submitting a biologics license application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP)... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,114 | +0,32 % | PacBio Grants Equity Incentive Award to New Employee | ||
| CARDIOL THERAPEUTICS | 0,799 | +7,97 % | Cardiol Therapeutics Aktie: Chancen verblassen? | Das biopharmazeutische Unternehmen macht wichtige Fortschritte in klinischen Studien für Perikarditis und Myokarditis-Behandlungen trotz aktueller Kursschwäche. Cardiol Therapeutics hat kürzlich bedeutende... ► Artikel lesen | |
| REDHILL BIOPHARMA | 1,900 | -14,41 % | RedHill Biopharma Ltd.: RedHill Biopharma to Submit FDA-Approved Talicia for UK Marketing Authorisation | RedHill plans to submit UK MAA1 for Talicia for H. pylori infection, using MHRA's2 new fast-track approval process, referencing FDA approval, with potential UK... ► Artikel lesen | |
| FIBROGEN | 0,272 | +4,61 % | FIBROGEN INC - 8-K, Current Report | ||
| ALLAKOS | 0,287 | -1,82 % | XFRA 37Z: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILALLAKOS INC. DL-... ► Artikel lesen | |
| VAXCYTE | 27,400 | -4,86 % | Goldman Sachs cuts Vaxcyte stock price target to $100 | ||
| VERRICA PHARMACEUTICALS | 0,410 | -15,39 % | Verrica Pharmaceuticals Inc. - 8-K, Current Report | ||
| HOOKIPA PHARMA | 0,850 | -0,05 % | HOOKIPA Pharma Inc. ("HOOKIPA") Statement regarding potential combination for Poolbeg Pharma plc ("Poolbeg") | NEW YORK and VIENNA, Austria, Feb. 20, 2025 (GLOBE NEWSWIRE) -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 1,215 | -3,57 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | DALLAS, April 04, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based... ► Artikel lesen | |
| QIAGEN | 35,330 | -2,40 % | Biotech Report: Kursgewinne bei Evotec und Qiagen | (shareribs.com) Frankfurt / New York 01.04.2025 - Biotech-Aktien zeigen sich im deutschen Handel überwiegend fester. Hierzulande legen unter anderem Biontech und Evotec zu. An der Wall Street sind die... ► Artikel lesen | |
| ADMA BIOLOGICS | 18,010 | -7,40 % | ADMA Biologics, Inc.: ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | FY 2024 Total Revenue of $426.5 Million, a 65% YoY Increase FY 2024 GAAP Net Income of $197.7 Million, Including an $84.3 Million Valuation Allowance Tax Benefit FY 2024 Adjusted EBITDA(1)... ► Artikel lesen | |
| BEAM THERAPEUTICS | 15,270 | -7,23 % | Biotech stocks plunge as FDA's Peter Marks resigns over RFK Jr. dispute, Moderna and Beam Therapeutics hit hard |
Das Unternehmen BIOMX INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -2,13 % bei einem Aktienkurs von 0,551 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOMX INC finden Sie auf Wallstreet Online.
